News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Results From Chelsea Therapeutics, Inc. (CHTP)' Pivotal Northera(TM) (Droxidopa) Study to be Presented at the American Academy of Neurology's Annual Meeting


4/27/2012 9:24:04 AM

CHARLOTTE, N.C., April 27, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced that Horacio Kaufmann, M.D., Professor of Medicine, NYU Langone Medical Center, New York, will present the full results from the previously reported Northeraâ„¢ (droxidopa) Study 301 during the oral Clinical Trials Forum at the American Academy of Neurology 64th Annual Meeting in New Orleans, Louisiana, at 12:15 PM ET today. Overall, the results of the study showed droxidopa demonstrated statistical improvement compared to placebo in the trial for the primary clinical endpoint (OHQ composite score), which provides a comprehensive measure of symptoms for neurogenic orthostatic hypotension (known as Neurogenic OH or NOH). The results were consistent irrespective of gender, concomitant medications or primary diagnosis.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES